12
Participants
Start Date
May 17, 2019
Primary Completion Date
September 30, 2021
Study Completion Date
December 31, 2023
Azacitidine
Given IV
Cytarabine
Given intrathecally and IV
Fludarabine Phosphate
Given IV
Methotrexate
Given intrathecally
Pevonedistat
Given IV
Therapeutic Hydrocortisone
Given intrathecally
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
Children's Hospital of Pittsburgh of UPMC, Pittsburgh
Children's Hospital of Philadelphia, Philadelphia
Children's National Medical Center, Washington D.C.
Children's Healthcare of Atlanta - Egleston, Atlanta
Children's Hospital of Alabama, Birmingham
Saint Jude Children's Research Hospital, Memphis
Cincinnati Children's Hospital Medical Center, Cincinnati
Riley Hospital for Children, Indianapolis
C S Mott Children's Hospital, Ann Arbor
University of Minnesota/Masonic Cancer Center, Minneapolis
Lurie Children's Hospital-Chicago, Chicago
Washington University School of Medicine, St Louis
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Children's Hospital Colorado, Aurora
Children's Hospital of Orange County, Orange
UCSF Medical Center-Mission Bay, San Francisco
Seattle Children's Hospital, Seattle
Dana-Farber Cancer Institute, Boston
Children's Oncology Group
NETWORK
National Cancer Institute (NCI)
NIH